Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB3 over exp prostate cancer sensitive HER3 (ERBB3) Antibody Patritumab deruxtecan Preclinical - Pdx & cell culture Actionable In a preclinical study, Patritumab deruxtecan (U3-1402) inhibited growth of patient-derived prostate cancer cells with high ERBB3 (HER3) expression in culture and in a patient-derived xenograft (PDX) model, but did not demonstrate anti-tumor activity in cell lines with low ERBB3 (HER3) expression (PMID: 34753775). 34753775
ERBB3 over exp prostate cancer predicted - sensitive HER3 (ERBB3) Antibody Patritumab Preclinical - Pdx & cell culture Actionable In a preclinical study, Patritumab (U3-1287) treatment decreased viability of patient-derived prostate cancer cells with high ERBB3 (HER3) expression in culture but did not inhibit tumor growth in a patient-derived xenograft (PDX) model, and did not demonstrate anti-tumor activity in cell lines with low ERBB3 (HER3) expression (PMID: 34753775). 34753775
ERBB3 over exp breast cancer sensitive HER3 (ERBB3) Antibody Patritumab deruxtecan Preclinical - Cell culture Actionable In a preclinical study, Patritumab deruxtecan (U3-1402) treatment inhibited growth of a breast cancer cell line overexpressing Erbb3 (Her3) in culture (PMID: 35503762). 35503762
ERBB3 over exp triple-receptor negative breast cancer predicted - sensitive HER3 (ERBB3) Antibody Patritumab deruxtecan Phase Ib/II Actionable In a Phase I/II trial (U31402-A-J101), Patritumab deruxtecan (U3-1402) therapy demonstrated safety and efficacy in previously treated metastatic triple-negative breast cancer patients with high ERBB3 (HER3) (>/=75% membrane positivity) levels (n=53), with an objective response rate of 22.6%, disease control rate of 79.2%, with partial response in 22.6% and stable disease in 56.6% of patients, median progression-free survival of 5.5 mo, and median overall survival of 14.6 mo (PMID: 37801674; NCT02980341). 37801674
ERBB3 over exp Her2-receptor positive breast cancer predicted - sensitive HER3 (ERBB3) Antibody Patritumab deruxtecan Phase Ib/II Actionable In a Phase I/II trial (U31402-A-J101), Patritumab deruxtecan (U3-1402) therapy demonstrated safety and efficacy in previously treated metastatic ERBB2 (HER2)-positive breast cancer patients with high ERBB3 (HER3) (>/=75% membrane positivity) levels (n=14), with an objective response rate of 42.9%, disease control rate of 92.9%, with partial response in 42.9% and stable disease in 50% of patients, median progression-free survival of 11 mo, and median overall survival of 19.5 mo (PMID: 37801674; NCT02980341). 37801674